NCT02205398 - Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 28, 2014

Primary Completion Date

January 20, 2017

Study Completion Date

January 20, 2017

Conditions

Squamous Cell Carcinoma of Head and Neck (SCCHN)Metastatic Colorectal Cancer

Interventions

DRUG

INC280

DRUG

cetuximab

Trial Locations (15)

Novartis Investigative Site, Leuven

Memorial Sloan Kettering MSKCC NY, New York

Novartis Investigative Site, Milan

Novartis Investigative Site, Toulouse

Novartis Investigative Site, Essen

Novartis Investigative Site, Valencia

Novartis Investigative Site, Ancona

Novartis Investigative Site, Lyon

University of Utah / Huntsman Cancer Institute Onc Dept, Salt Lake City

Novartis Investigative Site, Würzburg

Massachusetts General Hospital Head & Neck, Boston

Novartis Investigative Site, Toronto

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Barcelona

Novartis Investigative Site, L'Hospitalet de Llobregat